Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.
A Randomized, Double Blind, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of IBI306 in Healthy Subjects.
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
A PHASE1 clinical study on Hypercholesterolemia, this trial is completed. The trial is conducted by Innovent Biologics (Suzhou) Co. Ltd. and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2018 — Mar 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .